Alys Pharmaceuticals Inc., an immuno-dermatology focused company, has launched with an R&D pipeline enabled by multiple platform technologies and a $100 million financing by Medicxi.   Originating from the aggregation of six asset-centric Medicxi companies, Alys boasts a pipeline of programs and platforms targeting multiple dermatological indications. Aspiring to Redefine Dermatological Treatments Co-founded by Medicxi and several dermatology and scientific experts, including John Har...